The Incidental Genomic Finding: What to Do When a DTC Test Shows a BRCA Mutation

Managing Direct-to-Consumer Genetic Test Results in Primary Care

Dr Neeraj Manikath , claude.ai

Abstract

Direct-to-consumer (DTC) genetic testing has democratized access to genomic information, creating an unprecedented scenario where patients present to primary care with potentially life-altering genetic findings—often without adequate counseling or clinical context. BRCA mutations, associated with hereditary breast and ovarian cancer syndrome, are among the most clinically significant variants reported by DTC companies. This review provides a systematic approach for internists managing patients with incidental DTC-reported BRCA mutations, emphasizing the critical distinction between screening and diagnostic testing, the essential role of genetic counseling, and the coordination of confirmatory testing and surveillance. Understanding this pathway is no longer optional; it is an essential competency for contemporary internal medicine practice.

Introduction: The New Genomic Reality

The genomic revolution has arrived not through hospital doors, but through mailboxes. Over 30 million individuals worldwide have purchased DTC genetic tests, with companies like 23andMe, AncestryDNA, and others offering health-related genomic information alongside ancestry data. These tests have created a new clinical scenario: the anxious patient clutching printouts of genetic variants they barely understand, seeking guidance from primary care physicians who may feel equally unprepared.

BRCA1 and BRCA2 mutations represent some of the most clinically actionable findings in DTC testing. Women with pathogenic BRCA1 mutations face a cumulative breast cancer risk of 55-72% by age 80, compared to approximately 12% in the general population. For BRCA2, the risk is 45-69%. Ovarian cancer risks are similarly elevated: 39-44% for BRCA1 and 11-17% for BRCA2 carriers. Male BRCA2 carriers face increased risks of breast, prostate, and pancreatic cancers.

The challenge? DTC tests were designed as screening tools, not diagnostic instruments. They examine only a fraction of possible mutations, use different methodological standards than clinical testing, and provide results without the safeguards of traditional medical testing—pre-test counseling, clinical oversight, or interpretation support.

Pearl: When a patient presents with a DTC genetic result, your first responsibility is not to the genetic variant, but to the patient's understanding and emotional state. This is a moment that will define their relationship with their health for years to come.

The First Rule: Don't Panic (and Don't Act Immediately)

Understanding DTC Test Limitations

The first critical step is recognizing what DTC tests actually measure—and what they miss. Most DTC companies employ genotyping arrays that interrogate specific, pre-selected genetic variants rather than sequencing entire genes. For instance, the 23andMe FDA-authorized test for BRCA1/BRCA2 examines only three specific founder mutations common in Ashkenazi Jewish populations (BRCA1 185delAG, BRCA1 5382insC, and BRCA2 6174delT), which account for approximately 2% of all pathogenic BRCA variants in the general population.

This selective approach creates two profound problems:

False reassurance: A negative DTC test does not exclude BRCA mutations. Individuals of non-Ashkenazi ancestry with strong family histories may have other pathogenic variants entirely missed by DTC panels. Even among Ashkenazi individuals, other mutations exist beyond the three tested variants.

False positives: Technical artifacts, variant misclassification, and database errors can generate concerning results. DTC tests typically report raw genotype calls without the rigorous bioinformatic pipelines, Sanger confirmation, and clinical interpretation required for diagnostic testing. Studies have documented discordance rates between DTC and clinical testing ranging from 4% to 40% depending on the variant type.

Oyster: Not all "positive" DTC results are pathogenic mutations. Variants of uncertain significance (VUS), benign polymorphisms, and technical false positives can all trigger alarming reports. Never initiate cancer surveillance or prophylactic interventions based solely on DTC results.

The Clinical Context Matters

Before ordering confirmatory testing, perform a thorough personal and family cancer history assessment. The pre-test probability fundamentally influences post-test decision-making. Utilize validated tools like the Tyrer-Cuzick model or the NCCN guidelines criteria for genetic testing eligibility.

Key questions to document:

Personal history of breast, ovarian, pancreatic, or prostate cancer
Age at diagnosis for any cancers
Three-generation pedigree including both maternal and paternal lineages
Ancestry (Ashkenazi Jewish, Icelandic, Norwegian, Dutch, or French Canadian ancestry increases founder mutation prevalence)
Previous radiation therapy to the chest
Gender identity (transgender individuals retain hereditary cancer risks based on natal anatomy)

Hack: Use the "rule of threes" for quick BRCA risk assessment: Three affected relatives, cancer diagnosed before age 50 in three relatives, or three primary cancers in one individual should prompt genetic evaluation regardless of DTC testing.

"Clinical Grade" Confirmation is Mandatory

The Pathway from Screening to Diagnosis

No clinical decision should ever be based on DTC results alone. The American College of Medical Genetics and Genomics (ACMG) and National Society of Genetic Counselors (NSGC) have unequivocally stated that DTC results require confirmation through CLIA-certified, CAP-accredited laboratory testing before any medical intervention.

Why confirmatory testing is non-negotiable:

Different methodologies: Clinical BRCA testing employs next-generation sequencing of the entire coding sequence plus splice sites, often with deletion/duplication analysis. This detects mutations DTC tests cannot assess.
Variant interpretation standards: Clinical laboratories follow ACMG/AMP variant classification guidelines with rigorous evidence review, multidisciplinary adjudication, and regular reclassification as evidence evolves.
Quality assurance: Clinical laboratories maintain stringent validation standards, participate in proficiency testing, and provide interpretive reports signed by board-certified medical geneticists or molecular pathologists.
Medical-legal protection: Confirmatory testing through appropriate channels provides documentation necessary for insurance coverage of surveillance and risk-reducing interventions.

Ordering Confirmatory Testing: The Mechanics

Do not order confirmatory genetic testing yourself—yet. The optimal pathway involves genetic counseling before test ordering, which we'll address below. However, understanding the process helps you guide patients effectively.

When confirmatory testing is appropriate, order comprehensive BRCA1/BRCA2 sequencing and deletion/duplication analysis, not targeted mutation testing (unless the genetic counselor recommends otherwise based on family history). Simply testing for the specific variant reported by the DTC company is insufficient because:

It doesn't rule out other pathogenic mutations
It doesn't provide the comprehensive genetic information needed for family cascade testing
Insurance companies increasingly require comprehensive testing for coverage decisions

Cost considerations: Comprehensive BRCA testing through clinical laboratories typically costs $250-500 after insurance. Under the Affordable Care Act, genetic counseling and testing for individuals meeting USPSTF criteria are covered without cost-sharing. Many laboratories offer financial assistance programs, with some providing testing for under $100 for uninsured patients.

Pearl: Document that the confirmatory testing is being ordered because of a positive DTC result, not as routine screening. This distinction affects insurance coverage and prior authorization requirements.

The Role of Genetic Counseling

The Indispensable Intermediary

Genetic counseling is not a luxury or an optional adjunct—it is the standard of care. The complexity of genetic testing, the nuances of variant interpretation, the psychological impact of results, and the implications for family members all demand specialized expertise that exceeds the training of most internists.

When to refer for genetic counseling:

Immediately, before ordering confirmatory testing. This is the correct sequence: DTC result → genetic counseling → confirmatory testing → results disclosure through genetics → coordinated management.

What Genetic Counselors Provide

Genetic counselors offer services that extend far beyond test ordering:

Pedigree construction and risk assessment: Detailed three-generation family history analysis to contextualize the DTC finding and identify other at-risk relatives.
Pre-test education: Explanation of what confirmatory testing will and won't reveal, including the possibility of variants of uncertain significance (VUS), implications for family members, and potential insurance/employment discrimination concerns.
Informed consent: Documentation that the patient understands the implications, limitations, and potential outcomes of testing.
Results interpretation: Genetic counselors explain confirmatory test results in the context of the patient's specific situation, distinguishing between pathogenic mutations, likely pathogenic variants, VUS, and benign variants.
Psychosocial support: Assessment of coping mechanisms, family dynamics, and referral for mental health services when needed.
Cascade testing coordination: Guidance for at-risk family members regarding their testing options and timing.

Finding Genetic Counseling Services

Multiple resources exist for locating qualified genetic counselors:

National Society of Genetic Counselors directory: findageneticcounselor.nsgc.org
Cancer genetics programs at academic medical centers typically offer comprehensive services
Telegenetics services increasingly provide access in underserved areas, with studies demonstrating equivalent outcomes to in-person counseling

Average wait times for genetic counseling appointments range from 2-6 weeks in urban areas and up to 12 weeks in rural settings. Many programs offer "genetic counseling assistants" or "genetic coordinators" who can perform preliminary intake and education while awaiting counselor appointments.

Hack: Establish relationships with 2-3 genetic counseling practices before you need them. Having a warm referral pathway reduces patient anxiety and streamlines care. Many counselors will provide curbside consultation on whether a patient needs to be seen urgently or can wait.

Oyster: Some patients resist genetic counseling referral, viewing it as an unnecessary obstacle to "just getting the test done." Frame genetic counseling not as a barrier but as an essential protection—ensuring they get the right test, interpret results correctly, and understand options fully. Emphasize that genetic counselors are advocates who help patients navigate a complex system, not gatekeepers preventing access.

Managing Patient Anxiety While Awaiting Confirmation

The interval between DTC result and confirmed diagnosis creates profound uncertainty. For many patients, this represents the most psychologically distressing phase of the entire experience. Your role during this liminal period is both clinical and pastoral.

Providing Accurate Information

Frame uncertainty appropriately: "The DTC test suggests a possible finding that needs verification. Many DTC results don't confirm on clinical testing, which is why we follow this careful process."

Avoid premature interventions: Patients may arrive requesting immediate prophylactic mastectomy or oophorectomy. Gently but firmly explain that irreversible surgical decisions require confirmed diagnoses, not screening test results. This is not being overly cautious—it is protecting patients from harm.

Contextualize timelines: "The few weeks it takes to get genetic counseling and confirmatory testing seem long now, but they're brief compared to the decades this information will affect your health decisions. Getting it right matters more than getting it fast."

Psychological Support Strategies

Normalize anxiety: "Many people feel overwhelmed after receiving unexpected genetic information. These feelings are completely understandable and common."

Assess for clinical depression or anxiety disorders: Use validated screening tools (PHQ-9, GAD-7) if symptoms seem significant. The prevalence of major depression in individuals awaiting genetic test results approaches 20-25% in some studies.

Provide credible resources:

Facing Our Risk of Cancer Empowered (FORCE): facingourrisk.org
BRCA Exchange: brcaexchange.org (variant-specific information)
National Cancer Institute genetics information: cancer.gov/about-cancer/causes-prevention/genetics

Consider short-term anxiolytic therapy for patients with severe anxiety impairing function. SSRIs may be initiated if depressive symptoms are prominent, though benzodiazepines should be used cautiously and briefly given addiction potential.

Pearl: Schedule a follow-up appointment before genetic counseling. This demonstrates ongoing support and provides an opportunity to reassess psychological state. Many patients feel abandoned during the waiting period; proactive outreach prevents this.

What Not to Do

Don't minimize: Phrases like "try not to worry" or "it's probably nothing" invalidate legitimate concerns and erode trust.

Don't overpromise: Avoid statements like "we'll definitely figure this out" or "everything will be fine." Uncertainty is inherent to this process.

Don't initiate cancer surveillance based on DTC results. Premature mammography or MRI creates radiation exposure (for mammography), cost, and anxiety without established benefit for unconfirmed findings.

The Positive Confirmation: Coordinating Oncology Care

When Clinical Testing Confirms a Pathogenic Mutation

Approximately 40-60% of DTC-detected BRCA mutations confirm on clinical testing, though this varies substantially by ancestry and specific variant. When confirmation occurs, your role shifts to coordination and long-term relationship maintenance.

Immediate Steps Post-Confirmation

1. Refer to high-risk oncology or cancer genetics clinic

Specialized multidisciplinary clinics offer comprehensive risk assessment, surveillance planning, and risk-reduction counseling. These teams typically include:

Medical oncologists with cancer genetics expertise
Surgical oncologists specializing in risk-reducing procedures
Genetic counselors
Psychosocial support specialists
Reproductive specialists (for patients considering childbearing)

Timeframe for referral: Within 2-4 weeks of confirmed results. This is not an emergency requiring same-day referral, but should not languish for months.

2. Provide surveillance recommendations while awaiting specialty consultation

Based on current NCCN guidelines for BRCA mutation carriers:

For BRCA1/2 mutation carriers with intact breasts:

Clinical breast examination every 6-12 months starting at age 25
Annual mammography and breast MRI with contrast beginning at age 25-30 (or individualized based on family history)
Consider contrast-enhanced MRI alternating with mammography at 6-month intervals

For BRCA1/2 mutation carriers with ovaries:

Transvaginal ultrasound and CA-125 every 6 months beginning at age 30-35 (though these have limited sensitivity)
Risk-reducing salpingo-oophorectomy (RRSO) between ages 35-40 after childbearing is complete (this reduces ovarian cancer risk by 80-90% and breast cancer risk by approximately 50%)

For male BRCA2 carriers:

Prostate cancer screening with PSA and digital rectal examination annually beginning at age 40
Clinical breast examination annually
Consider pancreatic cancer surveillance protocols if strong family history

3. Document thoroughly

Electronic health record documentation should include:

Copy of DTC result
Copy of confirmatory clinical test report
Genetic counseling summary
Updated family pedigree
Surveillance plan
Specialty referrals made
Patient's expressed preferences regarding risk-reducing interventions

Long-Term Primary Care Role

You remain the medical home. Specialists manage cancer surveillance and risk reduction, but you coordinate overall care, manage comorbidities, and provide continuity. Key ongoing responsibilities include:

Annual verification of surveillance completion: Don't assume patients are completing recommended screening. Proactively check that mammograms, MRIs, and other studies occurred.

Psychosocial monitoring: Depression, anxiety, relationship strain, and body image concerns may emerge months to years after diagnosis. Regular screening during routine visits identifies problems early.

Medication management: Patients choosing chemoprevention (tamoxifen, raloxifene for breast cancer risk reduction) require monitoring for thromboembolism, endometrial changes, and menopausal symptoms.

Coordination with other specialists: BRCA carriers may develop complex care teams including gynecologic oncology, breast surgery, plastic surgery (for reconstruction), and reproductive endocrinology. Someone must integrate these recommendations—that someone is you.

Family cascade testing: Gently remind patients that first-degree relatives have a 50% chance of carrying the same mutation and should be informed about testing options. Genetic counselors lead this process, but primary care physicians reinforce its importance.

Hack: Create a flowsheet or health maintenance reminder specifically for BRCA carriers in your EMR. Include mammography, MRI, transvaginal ultrasound, CA-125, specialist appointments, and psychosocial screening. This prevents oversight and demonstrates systematic care.

Risk-Reducing Interventions: Your Counseling Role

While specialists perform risk-reducing surgeries, primary care physicians often field initial questions and concerns.

Risk-reducing mastectomy (RRM):

Reduces breast cancer risk by approximately 90-95%
Does not eliminate risk entirely (residual breast tissue remains)
Involves decisions about reconstruction type, timing, and nipple preservation
Significant impact on body image, sexuality, and psychological well-being
Not appropriate for all mutation carriers—individualized decision-making essential

Risk-reducing salpingo-oophorectomy (RRSO):

Reduces ovarian cancer risk by 80-90%
Reduces breast cancer risk by approximately 50% (via estrogen reduction)
Induces surgical menopause if performed premenopausal
Requires consideration of hormone replacement therapy (HRT is generally safe for BRCA carriers without breast cancer history until natural menopause age)
Timing considerations balance cancer risk against quality-of-life impacts

Your role: Provide balanced information, normalize ambivalence, and support informed decision-making. Phrases like "there's no one right answer—different people make different choices based on their values and circumstances" validate patient autonomy.

Special Populations and Considerations

Variants of Uncertain Significance (VUS)

Approximately 5-10% of comprehensive BRCA testing yields VUS rather than clearly pathogenic or benign variants. Management of VUS is challenging:

Do not initiate high-risk surveillance based on VUS alone
Base management on personal and family cancer history independent of the VUS
Encourage periodic reclassification through the testing laboratory (variants are reclassified as evidence accumulates)
Avoid cascade testing of family members for VUS

Pearl: VUS cause tremendous anxiety but require therapeutic nihilism. Resist pressure to "do something" when the evidence doesn't support intervention.

Male BRCA Carriers

Male patients often feel excluded from BRCA discussions focused on breast and ovarian cancer. Recognize that:

BRCA2 mutations confer substantially elevated prostate cancer risk (20-60% lifetime risk)
Male breast cancer, though rare, occurs at higher rates (1-5% for BRCA2, <1% for BRCA1)
Pancreatic cancer risk is increased, particularly with BRCA2
Male carriers transmit mutations to offspring at 50% probability

Young Adults and Reproductive Counseling

BRCA carriers of reproductive age face unique decisions:

Preimplantation genetic diagnosis (PGD) allows selection of embryos without the mutation
Prenatal testing via chorionic villus sampling or amniocentesis can determine fetal carrier status
Ethical complexity around testing for adult-onset conditions creates counseling challenges
Reproductive specialists with genetics expertise should be involved in these discussions

Conclusion: The Internist as Genomic Navigator

DTC genetic testing has permanently altered the landscape of primary care. The scenario of a patient presenting with a BRCA mutation detected through commercial testing is no longer rare or exotic—it is an expected competency for contemporary internists.

Your role encompasses reassurance during uncertainty, coordination of appropriate confirmatory testing, connection to genetic counseling expertise, and long-term partnership in cancer risk management. This is not about replacing specialists, but about ensuring patients navigate the complex path from incidental finding to informed decision-making safely and supported.

The genomic era has arrived in primary care. Our patients need us to meet it with knowledge, empathy, and systematic approaches that honor both the power and the limitations of genetic information.

Final Pearl: When in doubt, slow down. Genetic information is permanent; there is rarely urgency that justifies bypassing appropriate evaluation. Your patient will remember whether you panicked with them or guided them thoughtfully through uncertainty. Choose the latter.

References

Khoury MJ, Iademarco MF, Riley WT. Precision public health for the era of precision medicine. Am J Prev Med. 2016;50(3):398-401.
Tandy-Connor S, Guiltinan J, Krempely K, et al. False-positive results released by direct-to-consumer genetic tests highlight the importance of clinical confirmation testing for appropriate patient care. Genet Med. 2018;20(12):1515-1521.
Kalia SS, Adelman K, Bale SJ, et al. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0). Genet Med. 2017;19(2):249-255.
Kurian AW, Ward KC, Howlader N, et al. Genetic testing and results in a population-based cohort of breast cancer patients and ovarian cancer patients. J Clin Oncol. 2019;37(15):1305-1315.
Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017;317(23):2402-2416.
National Comprehensive Cancer Network. Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic (Version 3.2024). https://www.nccn.org/guidelines/guidelines-detail?category=2&id=1503
Robson M, Goessl C, Domchek S. Olaparib for metastatic germline BRCA-mutated breast cancer. N Engl J Med. 2017;377(18):1792-1793.
Buchanan AH, Lester Kirchner H, Schwartz MLB, et al. Clinical outcomes of a genomic screening program for actionable genetic conditions. Genet Med. 2020;22(11):1874-1882.
Otten E, Plantinga M, Birnie E, et al. Is there an optimal age for predicting risk? A comparison of the BOADICEA breast cancer prediction model at different life stages. Genet Med. 2015;17(3):228-236.
American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 182: Hereditary breast and ovarian cancer syndrome. Obstet Gynecol. 2017;130(3):e110-e126.

Conflict of Interest Statement: The author declares no conflicts of interest.

Acknowledgments: The author thanks genetic counselors and cancer genetics specialists whose expertise informs best practices in managing hereditary cancer syndromes.

Search This Blog

Internal medicine